Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2003
No trial phase data available
No trial data available
No trial data available
No approval data available
- Avacta's faridoxorubicin demonstrated clinically meaningful tumor shrinkage in 30% of salivary gland cancer patients, with two confirmed partial responses and seven minor responses in a Phase 1b trial. - The peptide drug conjugate achieved a 90% disease control rate across both Phase 1a and Phase 1b cohorts, targeting a cancer type that typically doesn't respond to chemotherapy. - Faridoxorubicin utilizes Avacta's preCISION platform to selectively deliver doxorubicin to tumor cells via fibroblast activation protein-alpha cleavage in the tumor microenvironment. - The treatment shows potential for addressing an unmet medical need in salivary gland cancer, which affects approximately 2,500 patients annually in the U.S. and has a five-year survival rate of 42% in advanced stages.
- Avacta Group has agreed to sell Coris Bioconcept SRL to 3B BlackBio Dx Ltd for £2.15 million upfront plus potential earn-outs of up to £615,000, completing its transformation into a pure-play therapeutics company. - The sale represents the final step in Avacta's strategic pivot away from diagnostics, following the earlier divestment of Launch Diagnostics in March 2025. - Proceeds will fund advancement of Avacta's preCISION platform for peptide drug conjugates targeting precision oncology treatments. - The transaction extends Avacta's cash runway into Q1 2026 and allows full focus on its tumor-targeting therapeutic pipeline powered by fibroblast activation protein technology.
- Avacta Group plc has appointed David Liebowitz, M.D., Ph.D. as Chief Medical Officer to lead clinical strategy and execution for its targeted cancer therapy pipeline. - Liebowitz brings over 30 years of experience in oncology drug development and has contributed to more than 25 Investigational New Drug applications throughout his career. - The company also appointed Yulii Bogatyrenko as business development advisor to strengthen corporate growth strategy and pipeline advancement. - These appointments come at a pivotal time as Avacta continues to advance its pre|CISION platform for targeted oncology drug delivery.
- AVA6000 demonstrates encouraging efficacy with durable RECIST responses in patients with FAP-positive solid tumors, aligning with a favorable safety profile. - The pre|CISION™ technology enables tumor-specific doxorubicin release, reducing cardiac toxicity and other side effects compared to conventional doxorubicin. - Pharmacokinetic analysis reveals AVA6000 extends doxorubicin's half-life and limits its distribution into normal tissues, enhancing tumor exposure. - Clinical data supports the potential of AVA6000 to treat a broad range of solid tumor patient populations with unmet clinical needs.
- Avacta Group acquired Coris BioConcept, a Belgium-based rapid diagnostic test manufacturer, for £7.4 million upfront with potential additional payments up to £3.0 million based on performance. - The acquisition adds a broad portfolio of professional-use rapid diagnostic tests for respiratory, gastroenteric, and blood-borne pathogens, including antibiotic resistance detection capabilities. - This strategic move complements Avacta's October 2022 acquisition of Launch Diagnostics and advances the company's goal of establishing a full-spectrum in-vitro diagnostics business. - Coris generated £4.6 million in revenue for 2022 with approximately 50% gross margins and operates from a newly constructed 10,700 ft² facility in Gembloux, Belgium.
